Lineage Cell Therapeutics, Inc. (LCTX)

Market Cap	237.97M
Revenue (ttm)	13.96M
Net Income (ttm)	-48.91M
Shares Out	169.98M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	446,718
Open	1.39
Previous Close	1.38
Day's Range	1.38 - 1.47
52-Week Range	1.02 - 1.79
Beta	1.61
Analysts	Buy
Price Target	6.12 (+337.14%)
Earnings Date	Mar 9, 2023

About LCTX

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic can...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Brian Culley
• Employees: 57
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: LCTX

Financial Performance

In 2021, LCTX's revenue was $4.34 million, an increase of 137.73% compared to the previous year's $1.83 million. Losses were -$43.02 million, 108.3% more than in 2020.

Analyst Forecast

According to 14 analysts, the average rating for LCTX stock is "Buy." The 12-month stock price forecast is $6.12, which is an increase of 337.14% from the latest price.

Price Target

$6.12

(337.14% upside)

Analyst Consensus: Buy